PD166326

PD166326

Biochem/physiol Actions

ATP-competitive dual BCR-ABL and Src kinase inhibitor

PD166326 is an ATP-competitive dual BCR-ABL and Src kinase inhibitor. In some studies it has been found to be more potent than imatinib with inhibition of cancer growth in the low nanomolar range or even picomolar range in various biological systems.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Solubility Form Assay Price Quantity
3573826 PD166326 white to light brown 100 SIGMA-ALDRICH DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£391.39 (exc VAT) per 25MG
-
+
3573827 PD166326 white to light brown 100 SIGMA-ALDRICH DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£121.32 (exc VAT) per 5MG
-
+